Rigel Pharmaceuticals, Inc. (RIGL) Stock Grade

About Rigel Pharmaceuticals, Inc.'s fundamentals

Rigel Pharmaceuticals is a small-cap biotech company with a market capitalization of $770.4 million that has demonstrated exceptional financial performance metrics, including a 64.2% year-over-year revenue increase, a net margin of 124.7%, and a return on equity of 93.8%. The company's unusually high profitability margins and strong return on equity suggest significant operational efficiency, though these figures may reflect a particular business cycle or accounting anomaly typical of smaller biotech firms. With a P/E ratio of 2.1, the company trades at a low valuation multiple relative to earnings, and the company does not currently pay a dividend.